English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Approximately 31,000 new cases of renal cell cancer are diagnosed annually in the United States, and the disease is responsible for an estimated 12,000 deaths each year.[1] One third of the patients present with metastatic disease and 30% to 40% of the remainder will eventually develop distal metastases.[2] The median survival of patients with metastases is only eight months, with a five-year survival rate of less than 10%.[3]

Update on the Role of Immunotherapy in the Management of Kidney Cancer